Abstract
The monoclonal antibody A33 recognises a tumour-associated antigen on human colorectal carcinoma, and has undergone preliminary evaluation in the clinic where selective localisation to hepatic metastases has been demonstrated [Welt et al. (1994) J. Clin. Oncol. 12, 1561-1571]. A33 and an A33 tri-fab fragment (TFM) were labelled with 90Y via a stable macrocyclic ligand for biodistribution and therapy studies in nude mice bearing SW1222 colon carcinoma xenografts. Biodistribution studies demonstrated tumour localisation for both A33 IgG and TFM with low bone, liver and kidney levels. Clearance of TFM from the blood was much faster than IgG and this led to lower tumour accumulation for TFM but superior tumour-blood ratios. The maximum per cent injected dose per g localised to tumour was 35.9% +/- 5.3% for A33 IgG and 12.9% +/- 4.6% for A33 TFM with tumour-blood ratios at 48 h after administration of 5.6 +/- 1.8 and 29.2 +/- 9.8 respectively. Autoradiography studies with 125I-labelled A33 IgG and TFM demonstrated a homogeneous distribution within tumour tissue which was not observed with other anti-colorectal tumour antibodies. TFM penetrated into the tumour tissue more rapidly than IgG. In therapy studies, a single dose of 90Y-A33 IgG (250 microCi per mouse) or 90Y-A33 TFM (300 microCi per mouse) led to complete regression of 2-week-old tumour xenografts with long-term tumour-free survivors. A transient drop in white blood cell count was observed with both IgG and TFM but was significantly more pronounced with IgG. The cell count fell to 8.4% of control for IgG, whereas with TFM cell counts fell to 51% of control before recovery. These results indicate that the more rapid blood clearance of 90Y-TFM confers reduced toxicity compared with 90Y-IgG although similar therapeutic effects are achieved. When the dose of 90Y-IgG was adjusted to give the same dose to tumour achieved with 300 microCi 90Y-TFM, a lesser therapeutic effect was observed. This may be owing to more rapid tumour penetration achieved with TFM. Both A33 IgG and TFM demonstrated potent anti-tumour effects against human tumour xenografts in this mouse model system. The stability of these 90Y-labelled conjugates and their effective tumour penetration are promising for the development of humanised reagents for clinical studies.
Full text
PDF











Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adam T. Radioiodination for therapy. Ann Clin Biochem. 1989 May;26(Pt 3):244–245. doi: 10.1177/000456328902600306. [DOI] [PubMed] [Google Scholar]
- Blumenthal R. D., Sharkey R. M., Kashi R., Goldenberg D. M. Comparison of therapeutic efficacy and host toxicity of two different 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int J Cancer. 1989 Aug 15;44(2):292–300. doi: 10.1002/ijc.2910440218. [DOI] [PubMed] [Google Scholar]
- Boxer G. M., Abassi A. M., Pedley R. B., Begent R. H. Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy. Br J Cancer. 1994 Feb;69(2):307–314. doi: 10.1038/bjc.1994.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Buchegger F., Pfister C., Fournier K., Prevel F., Schreyer M., Carrel S., Mach J. P. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments. J Clin Invest. 1989 May;83(5):1449–1456. doi: 10.1172/JCI114037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Buchegger F., Pèlegrin A., Delaloye B., Bischof-Delaloye A., Mach J. P. Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med. 1990 Jun;31(6):1035–1044. [PubMed] [Google Scholar]
- Buras R. R., Wong J. Y., Kuhn J. A., Beatty B. G., Williams L. E., Wanek P. M., Beatty J. D. Comparison of radioimmunotherapy and external beam radiotherapy in colon cancer xenografts. Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):473–479. doi: 10.1016/0360-3016(93)90069-8. [DOI] [PubMed] [Google Scholar]
- Cheung N. K., Landmeier B., Neely J., Nelson A. D., Abramowsky C., Ellery S., Adams R. B., Miraldi F. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst. 1986 Sep;77(3):739–745. doi: 10.1093/jnci/77.3.739. [DOI] [PubMed] [Google Scholar]
- Colcher D., Hand P. H., Nuti M., Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U S A. 1981 May;78(5):3199–3203. doi: 10.1073/pnas.78.5.3199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Colcher D., Milenic D., Roselli M., Raubitschek A., Yarranton G., King D., Adair J., Whittle N., Bodmer M., Schlom J. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res. 1989 Apr 1;49(7):1738–1745. [PubMed] [Google Scholar]
- DeNardo G. L., Kroger L. A., DeNardo S. J., Miers L. A., Salako Q., Kukis D. L., Fand I., Shen S., Renn O., Meares C. F. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer. 1994 Feb 1;73(3 Suppl):1012–1022. doi: 10.1002/1097-0142(19940201)73:3+<1012::aid-cncr2820731340>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
- Esteban J. M., Schlom J., Mornex F., Colcher D. Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. Eur J Cancer Clin Oncol. 1987 Jun;23(6):643–655. doi: 10.1016/0277-5379(87)90259-8. [DOI] [PubMed] [Google Scholar]
- Goldenberg D. M., Gaffar S. A., Bennett S. J., Beach J. L. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res. 1981 Nov;41(11 Pt 1):4354–4360. [PubMed] [Google Scholar]
- Harwood P. J., Britton D. W., Southall P. J., Boxer G. M., Rawlins G., Rogers G. T. Mapping epitope characteristics on carcinoembryonic antigen. Br J Cancer. 1986 Jul;54(1):75–82. doi: 10.1038/bjc.1986.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hyams D. M., Esteban J. M., Beatty B. G., Wanek P. M., Beatty J. D. Prolongation of survival of nude mice bearing human colon cancer. Treatment with yttrium 90-labeled anti-carcinoembryonic antigen antibody. Arch Surg. 1989 Feb;124(2):175–179. doi: 10.1001/archsurg.1989.01410020045007. [DOI] [PubMed] [Google Scholar]
- Jain R. K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst. 1989 Apr 19;81(8):570–576. doi: 10.1093/jnci/81.8.570. [DOI] [PubMed] [Google Scholar]
- Junghans R. P., Dobbs D., Brechbiel M. W., Mirzadeh S., Raubitschek A. A., Gansow O. A., Waldmann T. A. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy. Cancer Res. 1993 Dec 1;53(23):5683–5689. [PubMed] [Google Scholar]
- King D. J., Antoniw P., Owens R. J., Adair J. R., Haines A. M., Farnsworth A. P., Finney H., Lawson A. D., Lyons A., Baker T. S. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 1995 Dec;72(6):1364–1372. doi: 10.1038/bjc.1995.516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- King D. J., Turner A., Farnsworth A. P., Adair J. R., Owens R. J., Pedley R. B., Baldock D., Proudfoot K. A., Lawson A. D., Beeley N. R. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 1994 Dec 1;54(23):6176–6185. [PubMed] [Google Scholar]
- Knox S. J. Overview of studies on experimental radioimmunotherapy. Cancer Res. 1995 Dec 1;55(23 Suppl):5832s–5836s. [PubMed] [Google Scholar]
- Lane D. M., Eagle K. F., Begent R. H., Hope-Stone L. D., Green A. J., Casey J. L., Keep P. A., Kelly A. M., Ledermann J. A., Glaser M. G. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer. 1994 Sep;70(3):521–525. doi: 10.1038/bjc.1994.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Larson S. M., Carrasquillo J. A., Krohn K. A., Brown J. P., McGuffin R. W., Ferens J. M., Graham M. M., Hill L. D., Beaumier P. L., Hellström K. E. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest. 1983 Dec;72(6):2101–2114. doi: 10.1172/JCI111175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee Y. C., Washburn L. C., Sun T. T., Byrd B. L., Crook J. E., Holloway E. C., Steplewski Z. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques. Cancer Res. 1990 Aug 1;50(15):4546–4551. [PubMed] [Google Scholar]
- Lyons A., King D. J., Owens R. J., Yarranton G. T., Millican A., Whittle N. R., Adair J. R. Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng. 1990 Aug;3(8):703–708. doi: 10.1093/protein/3.8.703. [DOI] [PubMed] [Google Scholar]
- Maack T., Johnson V., Kau S. T., Figueiredo J., Sigulem D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 1979 Sep;16(3):251–270. doi: 10.1038/ki.1979.128. [DOI] [PubMed] [Google Scholar]
- Mach J. P., Pèlegrin A., Buchegger F. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr Opin Immunol. 1991 Oct;3(5):685–693. doi: 10.1016/0952-7915(91)90097-k. [DOI] [PubMed] [Google Scholar]
- Moi M. K., DeNardo S. J., Meares C. F. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res. 1990 Feb 1;50(3 Suppl):789s–793s. [PubMed] [Google Scholar]
- Pedley R. B., Boden J. A., Boden R., Dale R., Begent R. H. Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br J Cancer. 1993 Jul;68(1):69–73. doi: 10.1038/bjc.1993.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Badger C. C., Nelp W. B., Glenn S., Butchko G., Fisher D., Porter B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993 Oct 21;329(17):1219–1224. doi: 10.1056/NEJM199310213291702. [DOI] [PubMed] [Google Scholar]
- Richman P. I., Bodmer W. F. Control of differentiation in human colorectal carcinoma cell lines: epithelial-mesenchymal interactions. J Pathol. 1988 Nov;156(3):197–211. doi: 10.1002/path.1711560305. [DOI] [PubMed] [Google Scholar]
- Schott M. E., Frazier K. A., Pollock D. K., Verbanac K. M. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments. Bioconjug Chem. 1993 Mar-Apr;4(2):153–165. doi: 10.1021/bc00020a008. [DOI] [PubMed] [Google Scholar]
- Schott M. E., Schlom J., Siler K., Milenic D. E., Eggensperger D., Colcher D., Cheng R., Kruper W. J., Jr, Fordyce W., Goeckeler W. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer. 1994 Feb 1;73(3 Suppl):993–998. doi: 10.1002/1097-0142(19940201)73:3+<993::aid-cncr2820731337>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
- Senekowitsch R., Reidel G., Möllenstädt S., Kriegel H., Pabst H. W. Curative radioimmunotherapy of human mammary carcinoma xenografts with iodine-131-labeled monoclonal antibodies. J Nucl Med. 1989 Apr;30(4):531–537. [PubMed] [Google Scholar]
- Sharkey R. M., Motta-Hennessy C., Pawlyk D., Siegel J. A., Goldenberg D. M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990 Apr 15;50(8):2330–2336. [PubMed] [Google Scholar]
- Stephens S., Emtage S., Vetterlein O., Chaplin L., Bebbington C., Nesbitt A., Sopwith M., Athwal D., Novak C., Bodmer M. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology. 1995 Aug;85(4):668–674. [PMC free article] [PubMed] [Google Scholar]
- Washburn L. C., Lee Y. C., Sun T. T., Byrd B., Crook J. E., Stabin M. G., Steplewski Z. Preclinical assessment of 90Y-labeled monoclonal antibody CO17-1A, a potential agent for radioimmunotherapy of colorectal carcinoma. Int J Rad Appl Instrum B. 1988;15(6):707–711. doi: 10.1016/0883-2897(88)90065-7. [DOI] [PubMed] [Google Scholar]
- Welt S., Divgi C. R., Kemeny N., Finn R. D., Scott A. M., Graham M., Germain J. S., Richards E. C., Larson S. M., Oettgen H. F. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1994 Aug;12(8):1561–1571. doi: 10.1200/JCO.1994.12.8.1561. [DOI] [PubMed] [Google Scholar]
- Welt S., Divgi C. R., Real F. X., Yeh S. D., Garin-Chesa P., Finstad C. L., Sakamoto J., Cohen A., Sigurdson E. R., Kemeny N. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol. 1990 Nov;8(11):1894–1906. doi: 10.1200/JCO.1990.8.11.1894. [DOI] [PubMed] [Google Scholar]
- Yokota T., Milenic D. E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992 Jun 15;52(12):3402–3408. [PubMed] [Google Scholar]
- Yorke E. D., Beaumier P. L., Wessels B. W., Fritzberg A. R., Morgan A. C., Jr Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Int J Rad Appl Instrum B. 1991;18(8):827–835. doi: 10.1016/0883-2897(91)90090-8. [DOI] [PubMed] [Google Scholar]


